Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Tougeron

Showing results (131-140 of 235) with videos related to

Pageof 24
Sort By:
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
International Journal of Cancer|June 12, 2020
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancerCindy Neuzillet, Andrea Casadei-Gardini, Bertrand Brieau, et al.
British Journal of Cancer|September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortAlix Portal, Simon Pernot, David Tougeron, et al.
Cancer|June 9, 2015
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues OncologuesBertrand Brieau, Laetitia Dahan, Yann De Rycke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
Cancer Medicine|June 16, 2023
Prognostic value of Lynch syndrome, BRAF<sup>V600E</sup> , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohortsKoen Zwart, Frederieke H van der Baan, Romain Cohen, et al.
Molecular Oncology|December 4, 2024
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 studySusanne Klein-Scory, Alexander Baraniskin, Wolff Schmiegel, et al.
International Journal of Cancer|November 13, 2020
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohortThomas Aparicio, Magali Svrcek, Julie Henriques, et al.
Pageof 24

Showing results (131-140 of 235) with videos related to

Sort By:
Pageof 24
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
International Journal of Cancer|June 12, 2020
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancerCindy Neuzillet, Andrea Casadei-Gardini, Bertrand Brieau, et al.
British Journal of Cancer|September 16, 2015
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohortAlix Portal, Simon Pernot, David Tougeron, et al.
Cancer|June 9, 2015
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues OncologuesBertrand Brieau, Laetitia Dahan, Yann De Rycke, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
Cancer Medicine|June 16, 2023
Prognostic value of Lynch syndrome, BRAF<sup>V600E</sup> , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohortsKoen Zwart, Frederieke H van der Baan, Romain Cohen, et al.
Molecular Oncology|December 4, 2024
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer-results from the FIRE-4.5 studySusanne Klein-Scory, Alexander Baraniskin, Wolff Schmiegel, et al.
International Journal of Cancer|November 13, 2020
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohortThomas Aparicio, Magali Svrcek, Julie Henriques, et al.
Pageof 24